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OBJECTIVES The aim of the present study was to evaluate whether the effect of an early invasive treatment
strategy differed between patients sub-grouped according to their severity of myocardial
ischemia, as evaluated by quantitative electrocardiographic (ECG) analysis at the time of
presentation. The present study is a sub-study of the previously published Fast Revascular-
ization during InStability in Coronary artery disease trial (FRISC-II).
BACKGROUND An early invasive treatment strategy has been shown to be the preferable treatment for
non–ST-segment elevation acute coronary syndromes (ACS). The population of patients
with unstable coronary artery disease is heterogeneous regarding both the underlying
pathology and prognosis. Early risk stratification is important to select patient subgroups that
will benefit the most from a given treatment.
METHODS In 2,201 patients with non–ST-segment elevation ACS, the ischemic burden at hospital
admission was determined by quantitative measurements of ST-T-segment deviations on the
ECG. The patients were subsequently sub-grouped in tertiles based on the amount of
ST-segment deviation. The primary end point for this analysis was death or myocardial
infarction (MI) within one year after study inclusion.
RESULTS The invasive treatment strategy produced a reduction of 50% in death or MI among the
patients with intermediate or major ST-segment deviation. The findings were independent of
age, gender, or troponin T status. The patients with confounding factors precluding ST
analysis had a poor outcome regardless of the treatment strategy.
CONCLUSIONS Ischemic burden on the admission ECG identifies patients with ACS who benefit the most
from an invasive treatment strategy. When the standard ECG is scrutinized with complete
quantitative measurements, it provides independent information on prognosis and benefit of
treatment. (J Am Coll Cardiol 2003;41:905–15) © 2003 by the American College of
Cardiology Foundation
Patients with unstable coronary artery disease (CAD) are
heterogeneous regarding both their underlying pathology
and prognosis. Thus, early risk stratification is important in
selecting patient subgroups that will benefit the most from
a given treatment. Biochemical markers of myocardial damage,
such as troponin T (TnT) and I, have been found to identify
high-risk patients and even to indicate who will or will not
benefit from aggressive anti-thrombotic treatment (1–3).
We and other investigators have previously found that
admission electrocardiographic (ECG) variables carry sim-
ilar or even better prognostic information than troponin
measurements in patients with acute coronary syndromes
(ACS) (4,5). In the Fast Revascularization during InStabil-
ity in Coronary artery disease trial (FRISC-II) population,
qualitative analysis of ECG data predicted the treatment
outcome, either alone or in combination with TnT data
(6,7). Although efforts have been made into finding the
appropriate cut-off levels for troponin to predict prognosis
and treatment success, the quantitative findings on the
admission ECG have not yet been systematically inves-
tigated regarding their ability to identify treatment re-
sponders.
Accordingly, the aim of the present study was to test the
hypothesis that quantitative analysis of the admission ECG
can help identify patients with non–ST-segment elevation
ACS who might benefit the most from an invasive treat-
ment strategy. The hypothesis is that the patients with the
highest ischemic burden, as determined by ST-segment
deviation on the standard ECG, have the greatest benefit,
defined as improvement in mortality and morbidity, from an
aggressive treatment strategy.
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METHODS
The present work is a sub-study of the FRISC-II trial, a
randomized study of an early invasive versus early non-
invasive strategy in unstable CAD. Details on the study
design have been published elsewhere (8). Briefly, patients
were included in the study if they had chest pain within the
last 48 h, in combination with either elevation of cardiac
biomarkers or ST depression or T-wave inversion on the
ECG. The patients were randomized to one of four treat-
ment groups: invasive treatment and long-term dalteparin;
invasive treatment and placebo; non-invasive treatment and
long-term dalteparin; and non-invasive treatment and pla-
cebo. The design and results from the long-term dalteparin
versus placebo arm of the study have been described in detail
(9).
In the invasive arm, the target was to perform the
revascularization procedures (where indicated) within seven
days after admission to the hospital. Non-invasive treatment
included coronary angiography only when a patient had
refractory or recurrent symptoms or a positive exercise test
before discharge.
End points. The primary outcome of the FRISC-II trial
was death or myocardial infarction (MI) at six months, but
the patients were followed up for at least one year. Second-
ary end points were angina, re-admission to the hospital,
myocardial revascularization, and bleeding. Myocardial in-
farction was defined by the occurrence of two of three of the
classic criteria: typical chest pain, diagnostic ECG, or
elevation of biochemical markers of infarction (8). When
the present sub-study was carried out, one-year follow-up
data were available. Because these data confirmed the
findings from the six-month analysis documenting a benefit
of an invasive treatment strategy, one-year follow-up data
were used in this sub-study.
ECG data. A 12-lead ECG was obtained at admission, at
randomization, after the intervention, or at hospital dis-
charge, and then at three-month and six-month visits, as
well as when there was any suspicion of angina or MI. The
admission ECGs were quantitatively analyzed in the ECG
core laboratory at the Department of Medicine B, Rigshos-
pitalet, Copenhagen University Hospital, before any other
data, including end point data, were revealed. The Copen-
hagen ECG core laboratory was established post hoc, and
ECG data originating in this core laboratory were not
included in the FRISC-II main data base. The presence and
amount of ST-segment deviation and T-wave amplitudes
were measured in all leads except aVR, and the patients
were subsequently sub-grouped in tertiles based on the
amount of cumulative ST-segment deviation and number of
leads with ST-segment deviation exceeding 0.5 mm on the
admission ECG. A fourth subgroup included patients with
confounding factors excluding reliable ST-segment analysis.
Criteria used to define the confounding factors are shown in
Appendix A.
Biochemical data. At randomization, blood samples were
obtained from all patients and stored for central analysis of
TnT. Quantitative TnT analysis was performed centrally at
the biomarker core laboratory at Uppsala University Hos-
pital, using the Elecsys TnT third-generation assay (Roche
Diagnostics, Basel, Switzerland).
Angiographic data. The invasive strategy required coro-
nary angiography within seven days after study inclusion.
All angiograms were evaluated locally. An obstruction of at
least 50% was considered significant. Revascularization was
encouraged in all patients with an obstruction of 70% or
more in any significant coronary artery. The study protocol
recommended percutaneous coronary intervention (PCI) if
there were one or two target lesions, and coronary artery
bypass graft surgery (CABG) in the presence of three-vessel
or left main CAD.
Statistics. Data analysis was performed based on the
“intention-to-treat” principle. Relative risk ratios were cal-
culated by univariate analysis, whereas odds ratios (ORs)
were determined by multivariate logistic regression analysis.
For risk and ORs, 95% confidence intervals for the com-
bined end point of death and MI after one year of
follow-up, in relation to treatment strategy, were calculated.
The ORs were adjusted for the clinical variables of age,
gender, smoking, previous MI, diabetes, hypertension, and
admission TnT level, all pre-defined as important baseline
characteristics in the main study (8). The timing of end
points is illustrated by Kaplan-Meier plots.
Table 1. Presence of ECG Confounders at Presentation
Confounder
No. of
Patients %
Death/MI at
1 Year (n)
Death/MI
(%)
LBBB 43 (2) 11 25.5
RBBB 59 (3) 9 15.0
LAHB 130 (6) 16 12.3
LPHB 5 (0.2) 2 40.0
LVH 175 (8) 24 13.7
RVH 95 (4) 13 13.6
Paced rhythm 8 (0.4) 1 12.5
Suspected WPW syndrome 2 (0.09) 0 0
Low voltage 2 (0.09) 0 0
Total* 504* (23) 73 14.5
*Fourteen patients had RBBB and LAHB, and one patient had RBBB and LPHB.
For definitions, see Appendix A.
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
ECG  electrocardiogram, electrocardiographic
FRISC-II  Fast Revascularization during InStability in
Coronary artery disease trial
MI  myocardial infarction
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
TnT  troponin T
ULN  upper limit of normal
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To assess a possible interaction between ST-segment
deviation and treatment, multiple logistic regression analysis
was used. The following terms were included: ST-segment
deviation  randomized treatment, age, previous MI, dia-
betes, smoking, hypertension, TnT, and randomized treat-
ment in itself. The ST-segment variable was transformed to
a dichotomous variable (summed ST-segment deviation3
mm and 3 mm at the 50th percentile) for a more simple
interpretation.
A comparison of baseline characteristics, troponin values,
and angiographic data between the three ST-segment de-
viation groups was done by using the Kruskall-Wallis
analysis of variance median test (continuous variables) or the
Pearson chi-square test (categorical variables), as appropri-
ate. Comparisons between the ECG confounder group and
any of the three ST-segment deviation groups were done by
using the Mann-Whitney U test or chi-squared test.
The STATISTICA software program was used for data
processing and statistical analysis, except for the logistic
regression analysis and the test for interaction, which were
performed using the SPSS program (version 9.0).
RESULTS
The ECG data were available to the Copenhagen core
laboratory in 2,238 patients participating in the invasive
versus non-invasive treatment study. In 37 patients (1.6%),
parts of the admission ECG were missing or the ECG was
of very poor technical quality. Thus, the population con-
sisted of 2,201 patients with evaluable ECGs.
The patients were classified into subgroups according to
the total amount of ST-segment deviation (the summated
deviation in 11 leads and the total number of leads with
ST-segment deviation 0.5 mm) at admission. Tertile
values were used as cut-off limits to obtain three groups of
almost equal size. Finally, 504 patients (23%) had con-
founding factors on the ECG excluding ST-segment anal-
ysis. Table 1 lists the presence of these confounding factors
and the number of events occurring in this sub-population.
Tables 2 and 3 present the benefit of an invasive treatment
strategy when the patients are sub-grouped by cumulative
ST-segment deviation and by the number of leads with
0.5-mm ST-segment deviation. There was a definite
Table 2. Differences in Treatment Outcome at One Year: Patients Classified According to
Summed ST-Segment Deviation
Non-Invasive
Strategy
Invasive
Strategy
Relative Risk
(95% CI)
Adjusted OR*
(95% CI)
End point: death
ST-deviation group
0–2.5 mm 1.1% 1.5% 1.04 (0.21–5.12) 0.71 (0.09–5.79)
3–5.5 mm 4.9% 1.9% 0.33 (0.12–0.91) 0.35 (0.11–1.10)
6 mm 4.1% 2.7% 0.66 (0.26–1.64) 0.60 (0.20–1.81)
Confounder group 7.9% 4.7% 0.58 (0.26–1.32) 0.48 (0.19–1.23)
End point: death/MI
ST-deviation group
0–2.5 mm 9.3% 11.8% 1.25 (0.76–2.07) 1.26 (0.70–2.28)
3–5.5 mm 13.3% 6.2% 0.46 (0.28–0.78) 0.42 (0.23–0.80)
6 mm 19.4% 9.5% 0.49 (0.32–0.76) 0.41 (0.24–0.70)
Confounder group 15.5% 13.5% 0.88 (0.57–1.34) 0.85 (0.51–1.43)
*Adjusted for age, gender, previous MI, diabetes, hypertension, smoking status, and troponin T.
CI  confidence interval; MI  myocardial infarction; OR  odds ratio.
Table 3. Differences in Treatment Outcome at One Year: Patients Classified According to the
Total Number of Leads With ST-Segment Deviation
Non-Invasive
Strategy
Invasive
Strategy
Relative Risk
(95% CI)
Adjusted OR*
(95% CI)
End point: death
ST-deviation group
0–4 leads 2.1% 1.2% 0.41 (0.11–1.58) 0.25 (0.04–1.51)
5–7 leads 2.8% 2.3% 0.67 (0.23–1.99) 0.83 (0.24–2.87)
8 leads 6.3% 3.1% 0.50 (0.21–1.22) 0.42 (0.14–1.26)
Confounder group 7.9% 4.7% 0.58 (0.26–1.32) 0.48 (0.19–1.23)
End point: death/MI
ST-deviation group
0–4 leads 9.1% 10.0% 1.09 (0.68–1.74) 1.13 (0.65–1.97)
5–7 leads 15.7% 8.0% 0.51 (0.32–0.83) 0.45 (0.25–0.81)
8 leads 19.2% 8.5% 0.44 (0.27–0.73) 0.36 (0.19–0.67)
Confounder group 15.5% 13.5% 0.88 (0.57–1.34) 0.85 (0.51–1.43)
*Adjusted for age, gender, previous MI, diabetes, hypertension, smoking status, and troponin T.
Abbreviations as in Table 2.
907JACC Vol. 41, No. 6, 2003 Holmvang et al.
March 19, 2003:905–15 ECG Predicts Benefit of Invasive Treatment in ACS
benefit of the invasive treatment strategy in reducing the
risk of the combined end point death or MI among the
patients with intermediate or major ST-segment deviation,
defined either by the total amount of deviation or the
number of leads with ST-segment deviation. Even when
corrected for other baseline variables (gender, age, hyper-
tension, smoking, diabetes, previous MI, and TnT 0.03
mol/l) in multivariate logistic regression analysis, the risk
reduction obtained by the invasive strategy was not affected.
The invasive strategy reduced mortality among all the
subgroups except for the patients with minor ST-segment
changes defined by summed deviation. The numbers were
too small, however, to obtain statistical significance. The
patients with confounding ECG factors that precluded
Figure 1. (A–D) Kaplan-Meier plots of the incidence of death or myocardial infarction at one year, according to the amount of ST-segment deviation
(summed deviation in mm) on the admission electrocardiogram (ECG) and the treatment strategy. Continued on next page.
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ST-segment analysis had a relatively poor outcome, regard-
less of the treatment strategy. The timing of the combined
end point of death/MI is presented as Kaplan-Meier plots
(Figs. 1A to 1D and Figs. 2A to 2C).
Interaction analysis of the variable summed ST-segment
deviation  randomized treatment came out as significant
for predicting death or MI at 12 months (p  0.006) in a
multivariate logistic regression analysis including random-
ized treatment in itself, TnT status, and the aforementioned
baseline variables.
Figure 3 illustrates the benefit of invasive treatment when
the patients are classified into smaller subgroups according
to admission ECG findings.
Patient characteristics in relation to the ECG at presen-
tation. Table 4 shows the differences in baseline character-
istics when the patients are classified according to the
Figure 1 Continued..
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amount of ST-segment deviation at admission. The patients
with ECG confounders and with the most ST-segment
deviation at admission had a higher risk profile than the
remainder of the patients. Similar results were obtained
when the patients were grouped according to the number of
leads with ST-segment deviation instead of the total
amount (data not shown).
ST-segment deviation and TnT. Randomization TnT
levels rose with increasing ST-segment deviation, and both
the median TnT level and the number of TnT-positive
patients were higher among the patients with the most
ST-segment and ECG confounders (Table 5).
Angiographic findings and invasive procedure. Coronary
angiography was performed within seven days in 1,077
Figure 2. (A–C) Kaplan-Meier plots of the incidence of death or myocardial infarction at one year, according to the amount of ST-segment deviation
(number of leads with ST-segment deviation 0.5 mm) on the admission electrocardiogram and the treatment strategy. Continued on next page.
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(98.6%) of the 1,092 patients in the invasive group. Fifteen
patients (1.4%) did not undergo angiography. Table 6
depicts the angiographic findings among the patients in the
four subgroups. More patients in the minor ST-segment
deviation group had either no significant vessel disease or
one-vessel disease, whereas two- or three-vessel disease and
left main stenosis were 50% more common among the
patients with major ST-segment depression. The mode of
invasive procedure differed significantly between the sub-
groups. As a consequence of the angiographic findings, the
patients with minor ST-segment changes randomized to
the invasive strategy were more likely to undergo PCI,
whereas CABG was the favored procedure among patients
with major ST-segment deviation (Table 7).
Invasive procedures and procedure-related acute MI.
Because of the different definitions of procedure-related
acute MI during CABG (in which only new Q waves were
referred to as MI) and PTCA (in which elevation of
biomarkers was sufficient for diagnosing acute MI) (8), the
occurrence of procedure-related acute MI was separately
registered. Between 47% and 66% of all end point acute MIs
were procedure-related; however, despite more frequent use
of PCI for revascularization among patients with minor
ST-segment depression, the procedure-related acute MI
frequency was not significantly increased among these
patients.
Clinical course of patients randomized to a non-invasive
strategy. Of the 1,109 patients randomized to a non-
invasive strategy, 314 (28%) underwent coronary angiogra-
phy within the first 30 days, because of either a positive
exercise test or clinical symptoms. The patients who crossed
over to an invasive strategy had significantly more ischemia
on the admission ECG than the patients who continued to
be managed conservatively (median ST-segment deviation 5
mm [range 2.5 to 7.5] vs. 4 mm [range 2.5 to 6.5], p 
0.001).
DISCUSSION
Non-invasive risk stratification. In patients with ACS,
the amount of ischemia, as detected by ECG changes at
admission, is an indicator of poor prognosis (10–12).
These previous findings were confirmed in the present
study. The amount of ST-segment depression at admission
was related to poor outcome among patients treated accord-
ing to conventional principles. The rate of death or MI at
one-year follow-up was doubled among the patients with
major ST-segment deviation, compared with the patients
with only minor or no ST-segment changes. ST-segment
deviation was associated with a higher risk profile, higher
TnT levels, and more extensive CAD determined by an-
giography.
Admittedly, risk and treatment stratification based solely
on troponin measurement and the ECG might exclude
some high-risk patients from beneficial therapies. Hence, in
the Thrombolysis in Myocardial Infarction (TIMI) risk
score system, age (65 years), risk factors for CAD, known
coronary artery stenosis 50%, ST-segment deviation at
admission, at least two previous attacks of angina, use of
aspirin within the last seven days, and elevated biomarkers
have all been found to carry independent prognostic infor-
mation (13). The Platelet IIb/IIIa Underpinning the Re-
Figure 2 Continued.
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ceptor for Suppression of Unstable Ischemia Trial (PUR-
SUIT) found the most important baseline indicators of poor
prognosis to be age, increased heart rate and blood pressure,
ST-segment depression, signs of heart failure, and elevated
cardiac markers (14). The present study confirms the
findings from previous studies that ST-segment deviation
on the admission ECG is an important risk indicator in
patients admitted with an ACS. However, several of the
other variables from the TIMI risk score seem to be
associated with ST-segment deviation.
Benefit of invasive treatment. It has been shown that the
mere presence of ST-segment depression at a threshold of
0.5 mm identifies patients at high risk of death on long-
term follow-up after unstable angina/non–Q-wave MI (11).
The present study suggests that invasive treatment is effi-
cacious across wide ranges of extent and magnitude of
ST-segment changes, but the magnitude of this effect does
seem to increase with the quantity of the ST-segment
deviation. Also, the extent of CAD increases substantially
with an increasing amount of ST-segment deviation (i.e.,
patients with major ST-segment deviation had a threefold
higher incidence of left main stenosis than the patients with
only minor ST-segment changes).
We have previously shown that the inability to perform
analysis of the ECG at discharge is associated with a poor
outcome after an episode of unstable CAD (15). Because
disqualifying ECG changes, such as bundle branch block
and hypertrophy, will usually be present both at admission
and discharge, the results of the present study are not
surprising. The patients with ECG confounders resemble
the patients with major ST-segment depression in terms of
their TnT values, angiographic findings, and choice of
revascularization procedure. Despite the fact that these
“high-risk” patients seemed to benefit somewhat less from
an invasive treatment strategy than did the patients with
major ST-segment deviation, judged by the combined end
point, mortality alone was reduced by 42% by the invasive
strategy. The ECG confounders are probably indicators of
several severe underlying conditions like advanced age,
previous acute MI, and heart failure, leading to the same
high risk as in patients with major ST-segment depression
with similar TnT values.
The explanation for the apparent smaller benefit from
invasive treatment among the patients with minor ST-
segment deviation could hypothetically be sought in the
Figure 3. Unadjusted relative risk of death or myocardial infarction at one
year, according to the amount of ST-segment deviation (summed deviation
in mm) on the admission electrocardiogram and the treatment strategy.
Table 4. Baseline Characteristics
Variable
ST-Deviation
0–2.5 mm
ST-Deviation
>2.5–5.5 mm
ST-Deviation
>5.5 mm p Value
ECG Confounder
Group
Median age (yrs) 64.0 63.8 66.4 0.0002* 68.4†
Male gender (%) 57.0 68.0 73.2  0.0001 79.8‡
Previous acute MI (%) 18.7 19.5 25.7 0.007 27.7§
Previous PTCA (%) 4.2 3.6 2.5 NS 2.9
Previous CABG (%) 0.4 0.2 0.2 NS 0.6
Smoker (%) 32.0 32.3 30.2 NS 27.3
Hypertension (%) 24.8 28.9 31.7 0.03 35.2§
Hyperlipidemia (%) 11.6 10.6 11.0 NS 10.9
NIDDM (%) 8.0 6.7 7.2 NS 7.5
IDDM (%) 4.3 4.5 5.6 NS 5.0
EF 45% (%) 9.3 9.8 12.3 NS 19.5‡
*Kruskall-Wallis analysis of variance median test (three groups). †p  0.01 compared with major ST-deviation group (Mann-Whitney U test). ‡p  0.05 compared with major
ST-deviation group (chi-square test). §p  0.05 compared with intermediate ST-deviation group (chi-square test).
CABG  coronary artery bypass graft surgery; ECG  electrocardiographic; EF  ejection fraction; IDDM  insulin-dependent diabetes mellitus; MI  myocardial
infarction; NIDDM  non-insulin-dependent diabetes mellitus; NS  not significant; PTCA  percutaneous transluminal coronary angioplasty;   summated.
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pre-defined primary end point criteria. Peri-procedural MI
was diagnosed based primarily on biomarker elevation after
PCI, whereas the diagnosis of peri-operative MI during
CABG required new Q-waves on the ECG. Because
CABG was more common among the patients with major
ST-segment depression (due to more severe CAD), the
“risk” of a peri-procedural MI could paradoxically be lower.
However, by counting the rate of procedure-related acute
MI versus “spontaneous” acute MI, this was not the case.
Thus, the higher rate of end points among the invasively
treated patients in the minor ST-segment depression group
could not be explained by a higher rate of PCI-related
infarcts. Controversies still exist about the clinical relevance
of PCI-related infarcts (16–18). A recent analysis of data
from PURSUIT revealed that peri-procedural infarcts were
associated with the same prognosis as spontaneous infarcts,
as long as the infarcts were of similar size, as determined by
biomarker levels (19). These findings were confirmed in the
Treat Angina with Aggrastat and determine Cost of Ther-
apy with an Invasive or Conservative Strategy–
Thrombolysis In Myocardial Infarction-18 (TACTICS–
TIMI-18) study, where larger infarcts (creatine kinase, MB
isoenzyme 3 the upper limit of normal [ULN]) had the
same prognosis, regardless of origin, whereas the smaller
spontaneous infarcts (1 to 3 ULN) had a 10-fold increase
in mortality within six months, compared with PCI-related
infarcts of similar size (20). Whether small PTCA-related
infarcts have a similar or better prognosis than conventional
Q-wave infarcts associated with CABG remains to be
shown.
Compared with the recently published TACTICS–
TIMI-18 (21), in FRISC-II, only very few patients received
treatment with a glycoprotein IIb/IIIa inhibitor outside the
catheterization laboratory. The very early invasive treatment
strategy used in TACTICS produced the lowest event rate
ever in a trial of non–ST-segment elevation ACS. The
results of previous trials of glycoprotein IIb/IIIa inhibitors
(22), in combination with the low event rates in TACTICS,
should lead to a recommendation of glycoprotein inhibitors
for all patients with non–ST-segment elevation ACS.
Whether this treatment would have further increased the
benefit of the invasive treatment strategy in FRISC-II is
speculative, however.
In the TACTICS–TIMI-18 trial, ST-segment changes
on the standard ECG predicted a benefit from the early
aggressive treatment strategy, and so did TnT. When
stratified only according to the presence or absence of
ST-segment changes at baseline, the patients without ST-
segment changes had no benefit of an early invasive treat-
ment strategy. Similarly, subgroup analysis showed that the
52% of patients in FRISC-II without ST-segment changes
at baseline also had similar outcomes with the use of either
strategy (8).
Within the last years of the past century, “the troponin
hypothesis” gained support based on many trials on the
ACS, although the potential information from standard
ECG analysis has not been explored as extensively. Numer-
ous studies have tried to determine the best cut-off levels for
the various biochemical markers to identify high-risk pa-
tients with ACS. To do justice to the ECG, similar efforts
must be put forth into identifying the ECG variables
containing the most information.
Previous studies on the prognostic value of ECG analysis
have mostly concentrated on ST-segment deviation analy-
Table 5. Troponin T Values at Presentation
Variable
ST-Deviation
0–2.5 mm
ST-Deviation
>2.5–5.5 mm
ST-Deviation
>5.5 mm p Value
ECG Confounder
Group
TnT at randomization (g/l) 0.09 (0–0.47) 0.15 (0–0.61) 0.23 (0.05–0.69)  0.00001* 0.21 (0.02–0.67)†
TnT 0.1 g/l (%) 47.2 52.9 62.8  0.0001‡ 57.7§
*Kruskall-Wallis analysis of variance median test (three groups). †p 0.01 compared with “intermediate” group (Mann-Whitney U test). ‡Pearson chi-square test for trend (three
groups). §p  0.01 compared with “intermediate” group (chi-square test).
ECG  electrocardiographic;   summated; TnT  troponin T.
Table 6. Coronary Angiographic Findings (Invasive Group Only)
Angiographic Result
ST-Deviation
0–2.5 mm (n  255)
ST-Deviation
>2.5–5.5 mm (n  304)
ST-Deviation
>5.5 mm (n  259)
p Value
(Pearson Chi-Square
Test of Three Groups)
ECG Confounder
Group (n  259)
Visible thrombus 21 (8.2) 34 (11.2) 27 (10.4) NS 20 (7.7)
No significant CAD* 49 (19.2) 49 (16.1) 27 (10.4) 0.02 26 (10.0)†
One-vessel disease* 94 (36.9) 90 (29.6) 55 (21.2)  0.0001 72 (27.8)
Two-vessel disease* 50 (19.6) 91 (29.9) 61 (23.5) NS 62 (23.9)
Three-vessel disease* 51 (20.0) 56 (18.4) 84 (32.4)  0.001 75 (29.0)‡
Main stem stenosis 11 (4.3) 18 (5.9) 32 (12.4) 0.001 23 (8.9)
Two- or three-vessel disease
or main stem stenosis
112 (43.9) 165 (54.2) 176 (68.3)  0.00001 160 (61.8)§
Not assessable 1 4 3 8
*Without concomitant left main stenosis. †p  0.05 compared with “intermediate” group (chi-square test). ‡p  0.01 compared with “intermediate” group (chi-square test).
§p  0.08 compared with “intermediate” group (chi-square test). Data are presented as the number (%) of patients.
CAD  coronary artery disease; ECG  electrocardiographic; NS  not significant;   summated.
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sis, and the results on prognostic information of isolated
T-wave inversion are conflicting. A future sub-study on the
FRISC-II population will hopefully reveal whether addi-
tional prognostic information can be extracted from careful
analysis of the T wave.
Study limitations. The present study is based on a post hoc
analysis of data from the FRISC-II trial. Subgroup analyses
may be underpowered; hence, the results of post hoc analysis
should be handled with care. The troponin cut-off level at
0.03 to 0.1 g/l and the ST-segment thresholds were
established based on a review of the data not tested
prospectively. Also, the different rates of CABG and PCI in
the subgroups are potential confounding factors that could
have influenced the occurrence of end points. Even though
the results of the present study indicate that an invasive
treatment strategy is beneficial only in patients with a
certain extent of ST-segment deviation on their admission
ECG, such a conclusion cannot be made without a ran-
domized trial aimed at this specific question. Based on the
FRISC-II results, an invasive treatment strategy should be
recommended for all patients with ACS who fulfill the
original inclusion criteria of the trial.
Conclusions. The present study supports the fact that the
standard ECG remains an easy available, inexpensive
method of risk stratifying patients with acute chest pain.
When ECG data are carefully handled, the ECG provides
independent information on prognosis and benefit of treat-
ment. Thus, the present study suggests that quantitative
ECG data and troponin measurements should be consid-
ered as complementary; they constitute the two most useful
non-invasive tests in patients with non–ST-segment eleva-
tion ACS. ST-segment depression should be included in
the risk models for assessment of prognosis in ACS.
Furthermore, when resources for early revascularization
therapy are limited, careful analysis of the ECG could help
identify patients who might benefit the most from an
invasive treatment strategy and, just as important, which
patients can initially be allocated to a less aggressive ap-
proach starting with antithrombic treatment and referred to
elective cardiac catheterization based on stress testing and
symptoms.
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APPENDIX A
Definition of Confounders
LBBB  left bundle branch block
RBBB  right bundle branch block
LAHB  left anterior hemi block
LPHB  left posterior hemi block
LVH  left ventricular hypertrophy
RVH  Right ventricular hypertrophy
WPW  Wolf-Parkinson-White syndrome
LBBB  left bundle branch block: QRS duration 120 ms
and typical configuration
RBBB  right bundle branch block: QRS duration 120
ms and typical configuration
LAHB left anterior hemi-block: QRS axis between45°
and 90° and rS configuration in leads II, III, and aVF
LPHB left posterior hemi-block: QRS axis120° and rS
configuration in leads I and aVL
LVH  left ventricular hypertrophy: at least two of the
following criteria (1,2):
1. Sokolow-Lyon: S amplitude in lead V1 R amplitude
in lead V5 or V6 35 mm
2. Cornell voltage: S amplitude in lead V3  R ampli-
tude in lead aVL (men: 28 mm, women 20 mm)
3. Romhilt-Estes: scoring system—possible LVH  4
points; definite LVH  5 points; ST-segment devia-
tion opposite QRS complex  3 points: S amplitude
in leads V1 to V3 25 mm 3 points; R amplitude in
leads V4 to V6 25 mm  3 points; R or S amplitude
in leads I, II, III, aVL, or aVF 20 mm  3 points;
terminal (downsloping) P-wave duration 40 ms  3
points; left axis15° 2 points; and QRS duration
90 ms  1 point
RVH  right ventricular hypertrophy: R (lead V1 or V2) 
S (lead V6 or I)  S (lead V1) 0.7 mV
WPW  Wolf-Parkinson-White syndrome: PR 120 ms,
wide QRS complex, delta wave
Low voltage: R  S amplitude 0.5 mV in leads I, II, III,
aVL, and aVF and R  S amplitude 1.0 mV in the
precordial leads
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